dr kim hye son glutathione ABOUT US Hye Sung Kim - Internal
Description
Int J Epidemiol 2016
IV therapy is particularly beneficial for patients who may have nutrient deficiencies or absorption issues
GHRH Peptides Side-by-Side Feature Receptor Target Tesamorelin GHRH receptor Sermorelin GHRH receptor CJC-1295 (DAC) GHRH receptor Feature Peptide Length Tesamorelin 44 amino acids (modified) Sermorelin 29 amino acids CJC-1295 (DAC) 29 amino acids + DAC Feature Half-Life Tesamorelin 26-38 minutes Sermorelin 11-12 minutes CJC-1295 (DAC) ~6-8 days Feature Dosing Frequency Tesamorelin Once daily Sermorelin Once nightly CJC-1295 (DAC) 1-2x weekly Feature FDA Status Tesamorelin Approved (2010
Yes, batch-specific COAs are available where applicable.
